133 related articles for article (PubMed ID: 27900832)
1. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.
Jiménez I; Baruchel A; Doz F; Schulte J
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27900832
[TBL] [Abstract][Full Text] [Related]
2. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
3. The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
Shi J; Vakoc CR
Mol Cell; 2014 Jun; 54(5):728-36. PubMed ID: 24905006
[TBL] [Abstract][Full Text] [Related]
4. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
Braun T; Gardin C
Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain inhibitors: what does the future hold?
Bhattacharya S; Piya S; Borthakur G
Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.
Niu N; Shao R; Yan G; Zou W
J Biol Chem; 2016 Dec; 291(52):26647-26657. PubMed ID: 27821592
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
10. Targeting the BET family for the treatment of leukemia.
Lucas X; Günther S
Epigenomics; 2014 Apr; 6(2):153-5. PubMed ID: 24811781
[No Abstract] [Full Text] [Related]
11. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Odore E; Lokiec F; Cvitkovic E; Bekradda M; Herait P; Bourdel F; Kahatt C; Raffoux E; Stathis A; Thieblemont C; Quesnel B; Cunningham D; Riveiro ME; Rezaï K
Clin Pharmacokinet; 2016 Mar; 55(3):397-405. PubMed ID: 26341814
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
13. Development of methyl isoxazoleazepines as inhibitors of BET.
Hewitt MC; Leblanc Y; Gehling VS; Vaswani RG; Côté A; Nasveschuk CG; Taylor AM; Harmange JC; Audia JE; Pardo E; Cummings R; Joshi S; Sandy P; Mertz JA; Sims RJ; Bergeron L; Bryant BM; Bellon S; Poy F; Jayaram H; Tang Y; Albrecht BK
Bioorg Med Chem Lett; 2015 May; 25(9):1842-8. PubMed ID: 25851940
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.
Tinsley S; Meja K; Shepherd C; Khwaja A
Br J Haematol; 2015 Jul; 170(2):275-8. PubMed ID: 25640480
[No Abstract] [Full Text] [Related]
15. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
Dittmann A; Werner T; Chung CW; Savitski MM; Fälth Savitski M; Grandi P; Hopf C; Lindon M; Neubauer G; Prinjha RK; Bantscheff M; Drewes G
ACS Chem Biol; 2014 Feb; 9(2):495-502. PubMed ID: 24533473
[TBL] [Abstract][Full Text] [Related]
16. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
18. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
19. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
20. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
